Novo Nordisk has filed for European approval for its long-acting insulin product Degludec and insulin combination analogue DegludecPlus, directly competing with Sanofi’s Lantus.

The Danish pharmaceutical firm has submitted the applications on the basis of results from the BEGIN and BOOST trial programmes, which enrolled almost 10,000 type 1 and type 2 diabetes patients and posted positive results in lowering blood glucose levels.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Degludec also demonstrated a significantly lower rate of hypoglycaemia in comparison to Sanofi’s insulin product Lantus.

Lantus is currently the world’s biggest selling insulin product, responsible for revenues totalling $3.5bn in 2010, but Degludec is expected to be a considerable challenger.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact